Cargando…
Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma
High-throughput sequencing of cell-free DNA (cfDNA) has emerged as a promising noninvasive approach in lymphomas, being particularly useful when a biopsy specimen is not available for molecular analysis, as it frequently occurs in primary mediastinal large B-cell lymphoma (PMBL). We used cfDNA for g...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324191/ https://www.ncbi.nlm.nih.gov/pubmed/35885481 http://dx.doi.org/10.3390/diagnostics12071575 |
_version_ | 1784756747071651840 |
---|---|
author | Rivas-Delgado, Alfredo Nadeu, Ferran Andrade-Campos, Marcio López, Cristina Enjuanes, Anna Mozas, Pablo Frigola, Gerard Colomo, Luis Sanchez-Gonzalez, Blanca Villamor, Neus Beà, Sílvia Campo, Elías Salar, Antonio Giné, Eva López-Guillermo, Armando Bellosillo, Beatriz |
author_facet | Rivas-Delgado, Alfredo Nadeu, Ferran Andrade-Campos, Marcio López, Cristina Enjuanes, Anna Mozas, Pablo Frigola, Gerard Colomo, Luis Sanchez-Gonzalez, Blanca Villamor, Neus Beà, Sílvia Campo, Elías Salar, Antonio Giné, Eva López-Guillermo, Armando Bellosillo, Beatriz |
author_sort | Rivas-Delgado, Alfredo |
collection | PubMed |
description | High-throughput sequencing of cell-free DNA (cfDNA) has emerged as a promising noninvasive approach in lymphomas, being particularly useful when a biopsy specimen is not available for molecular analysis, as it frequently occurs in primary mediastinal large B-cell lymphoma (PMBL). We used cfDNA for genomic characterization in 20 PMBL patients by means of a custom NGS panel for gene mutations and low-pass whole-genome sequencing (WGS) for copy number analysis (CNA) in a real-life setting. Appropriate cfDNA to perform the analyses was obtained in 18/20 cases. The sensitivity of cfDNA to detect the mutations present in paired FFPE samples was 69% (95% CI: 60–78%). The mutational landscape found in cfDNA samples was highly consistent with that of the tissue, with the most frequently mutated genes being B2M (61%), SOCS1 (61%), GNA13 (44%), STAT6 (44%), NFKBIA (39%), ITPKB (33%), and NFKBIE (33%). Overall, we observed a 75% concordance to detect CNA gains/losses between DNA microarray and low-pass WGS. The sensitivity of low-pass WGS was remarkably higher for clonal CNA (18/20, 90%) compared to subclonal alterations identified by DNA microarray. No significant associations between cfDNA amount and tumor burden or outcome were found. cfDNA is an excellent alternative source for the accurate genetic characterization of PMBL cases. |
format | Online Article Text |
id | pubmed-9324191 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93241912022-07-27 Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma Rivas-Delgado, Alfredo Nadeu, Ferran Andrade-Campos, Marcio López, Cristina Enjuanes, Anna Mozas, Pablo Frigola, Gerard Colomo, Luis Sanchez-Gonzalez, Blanca Villamor, Neus Beà, Sílvia Campo, Elías Salar, Antonio Giné, Eva López-Guillermo, Armando Bellosillo, Beatriz Diagnostics (Basel) Article High-throughput sequencing of cell-free DNA (cfDNA) has emerged as a promising noninvasive approach in lymphomas, being particularly useful when a biopsy specimen is not available for molecular analysis, as it frequently occurs in primary mediastinal large B-cell lymphoma (PMBL). We used cfDNA for genomic characterization in 20 PMBL patients by means of a custom NGS panel for gene mutations and low-pass whole-genome sequencing (WGS) for copy number analysis (CNA) in a real-life setting. Appropriate cfDNA to perform the analyses was obtained in 18/20 cases. The sensitivity of cfDNA to detect the mutations present in paired FFPE samples was 69% (95% CI: 60–78%). The mutational landscape found in cfDNA samples was highly consistent with that of the tissue, with the most frequently mutated genes being B2M (61%), SOCS1 (61%), GNA13 (44%), STAT6 (44%), NFKBIA (39%), ITPKB (33%), and NFKBIE (33%). Overall, we observed a 75% concordance to detect CNA gains/losses between DNA microarray and low-pass WGS. The sensitivity of low-pass WGS was remarkably higher for clonal CNA (18/20, 90%) compared to subclonal alterations identified by DNA microarray. No significant associations between cfDNA amount and tumor burden or outcome were found. cfDNA is an excellent alternative source for the accurate genetic characterization of PMBL cases. MDPI 2022-06-28 /pmc/articles/PMC9324191/ /pubmed/35885481 http://dx.doi.org/10.3390/diagnostics12071575 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rivas-Delgado, Alfredo Nadeu, Ferran Andrade-Campos, Marcio López, Cristina Enjuanes, Anna Mozas, Pablo Frigola, Gerard Colomo, Luis Sanchez-Gonzalez, Blanca Villamor, Neus Beà, Sílvia Campo, Elías Salar, Antonio Giné, Eva López-Guillermo, Armando Bellosillo, Beatriz Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma |
title | Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma |
title_full | Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma |
title_fullStr | Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma |
title_full_unstemmed | Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma |
title_short | Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma |
title_sort | cell-free dna for genomic analysis in primary mediastinal large b-cell lymphoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324191/ https://www.ncbi.nlm.nih.gov/pubmed/35885481 http://dx.doi.org/10.3390/diagnostics12071575 |
work_keys_str_mv | AT rivasdelgadoalfredo cellfreednaforgenomicanalysisinprimarymediastinallargebcelllymphoma AT nadeuferran cellfreednaforgenomicanalysisinprimarymediastinallargebcelllymphoma AT andradecamposmarcio cellfreednaforgenomicanalysisinprimarymediastinallargebcelllymphoma AT lopezcristina cellfreednaforgenomicanalysisinprimarymediastinallargebcelllymphoma AT enjuanesanna cellfreednaforgenomicanalysisinprimarymediastinallargebcelllymphoma AT mozaspablo cellfreednaforgenomicanalysisinprimarymediastinallargebcelllymphoma AT frigolagerard cellfreednaforgenomicanalysisinprimarymediastinallargebcelllymphoma AT colomoluis cellfreednaforgenomicanalysisinprimarymediastinallargebcelllymphoma AT sanchezgonzalezblanca cellfreednaforgenomicanalysisinprimarymediastinallargebcelllymphoma AT villamorneus cellfreednaforgenomicanalysisinprimarymediastinallargebcelllymphoma AT beasilvia cellfreednaforgenomicanalysisinprimarymediastinallargebcelllymphoma AT campoelias cellfreednaforgenomicanalysisinprimarymediastinallargebcelllymphoma AT salarantonio cellfreednaforgenomicanalysisinprimarymediastinallargebcelllymphoma AT gineeva cellfreednaforgenomicanalysisinprimarymediastinallargebcelllymphoma AT lopezguillermoarmando cellfreednaforgenomicanalysisinprimarymediastinallargebcelllymphoma AT bellosillobeatriz cellfreednaforgenomicanalysisinprimarymediastinallargebcelllymphoma |